Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology
Abstract Background PIK3CA mutations are implicated in various cancers, but the implications of multiple concurrent mutations and their orientations within the gene have not been fully explored. Methods In this study, we analyzed multi‐PIK3CA mutations across a diverse pan‐cancer cohort comprising 3...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846115497880322048 |
|---|---|
| author | Kohei Nakamura Marin Ishikawa Ryutaro Kawano Eriko Aimono Takaaki Mizuno Sachio Nohara Shigeki Tanishima Hideyuki Hayashi Hiroshi Nishihara The Keio PleSSision Group |
| author_facet | Kohei Nakamura Marin Ishikawa Ryutaro Kawano Eriko Aimono Takaaki Mizuno Sachio Nohara Shigeki Tanishima Hideyuki Hayashi Hiroshi Nishihara The Keio PleSSision Group |
| author_sort | Kohei Nakamura |
| collection | DOAJ |
| description | Abstract Background PIK3CA mutations are implicated in various cancers, but the implications of multiple concurrent mutations and their orientations within the gene have not been fully explored. Methods In this study, we analyzed multi‐PIK3CA mutations across a diverse pan‐cancer cohort comprising 3564 tumors. Results Multi‐PIK3CA mutations were present in 10.3% of all PIK3CA‐mutant tumors, predominantly occurring in breast and gynecological cancers. Notably, mutations within the helical domain (E542:E545) exclusively occurred in the trans‐orientation, contrasting with mutations in the kinase ABD and C2 domains, which mainly appeared in the cis orientation. Conclusions The distinct pattern of mutation orientations in PIK3CA suggests variable oncogenic potential, with helical domain mutations in the trans‐orientation potentially being less oncogenic. These findings highlight the importance of mutation orientation in the PIK3CA gene as potential biomarkers for targeted therapy. This understanding is crucial for designing clinical trials that leverage PI3K inhibitors, aiming for more effective and precise cancer treatment. |
| format | Article |
| id | doaj-art-f8b25879d84a45d8bad0b84914e2b944 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-f8b25879d84a45d8bad0b84914e2b9442024-12-19T12:33:09ZengWileyCancer Medicine2045-76342024-07-011314n/an/a10.1002/cam4.70052Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncologyKohei Nakamura0Marin Ishikawa1Ryutaro Kawano2Eriko Aimono3Takaaki Mizuno4Sachio Nohara5Shigeki Tanishima6Hideyuki Hayashi7Hiroshi Nishihara8The Keio PleSSision GroupGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanDepartment of Biomedical Informatics, Communication Engineering Center, Electronic Systems Business Group Mitsubishi Electric Software Co., Ltd. Amagasaki Hyogo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanGenomics Unit, Keio Cancer Center Keio University School of Medicine Shinjuku‐ku, Tokyo JapanAbstract Background PIK3CA mutations are implicated in various cancers, but the implications of multiple concurrent mutations and their orientations within the gene have not been fully explored. Methods In this study, we analyzed multi‐PIK3CA mutations across a diverse pan‐cancer cohort comprising 3564 tumors. Results Multi‐PIK3CA mutations were present in 10.3% of all PIK3CA‐mutant tumors, predominantly occurring in breast and gynecological cancers. Notably, mutations within the helical domain (E542:E545) exclusively occurred in the trans‐orientation, contrasting with mutations in the kinase ABD and C2 domains, which mainly appeared in the cis orientation. Conclusions The distinct pattern of mutation orientations in PIK3CA suggests variable oncogenic potential, with helical domain mutations in the trans‐orientation potentially being less oncogenic. These findings highlight the importance of mutation orientation in the PIK3CA gene as potential biomarkers for targeted therapy. This understanding is crucial for designing clinical trials that leverage PI3K inhibitors, aiming for more effective and precise cancer treatment.https://doi.org/10.1002/cam4.70052cismulti‐PIK3CA mutationsPI3K inhibitorprecision oncologytrans |
| spellingShingle | Kohei Nakamura Marin Ishikawa Ryutaro Kawano Eriko Aimono Takaaki Mizuno Sachio Nohara Shigeki Tanishima Hideyuki Hayashi Hiroshi Nishihara The Keio PleSSision Group Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology Cancer Medicine cis multi‐PIK3CA mutations PI3K inhibitor precision oncology trans |
| title | Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology |
| title_full | Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology |
| title_fullStr | Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology |
| title_full_unstemmed | Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology |
| title_short | Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncology |
| title_sort | characterizing multi pik3ca mutations across cancer types toward precision oncology |
| topic | cis multi‐PIK3CA mutations PI3K inhibitor precision oncology trans |
| url | https://doi.org/10.1002/cam4.70052 |
| work_keys_str_mv | AT koheinakamura characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT marinishikawa characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT ryutarokawano characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT erikoaimono characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT takaakimizuno characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT sachionohara characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT shigekitanishima characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT hideyukihayashi characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT hiroshinishihara characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology AT thekeioplessisiongroup characterizingmultipik3camutationsacrosscancertypestowardprecisiononcology |